Metabolic-associated fatty liver disease and older age

With the growing obesity epidemic around the world, metabolic associated fatty liver disease (MAFLD), formerly called non-alcoholic fatty liver disease (NAFLD), has become a common cause of liver disease, including in older age groups, the incidence of which is increasing significantly due to significant social change economic development and improvements in health care over recent years. While NAFLD primarily focuses on the accumulation of fat in the liver, MAFLD considers both the presence of fatty tissue in the liver and associated metabolic risk factors such as diabetes mellitus, dyslipidemia or obesity, providing a more detailed approach to diagnosis and treatment of steatotic liver disease. Thus, the introduction of the term MAFLD reflects a more comprehensive approach to encompass the diverse spectrum of patients affected by this disease and recognizes the complex relationship between metabolic disorders and liver health. Age-associated structural changes can significantly affect the morphology, physiology and oxidative capacity of the liver. With age, the weight of the liver decreases, the functionality of liver cells decreases, leading to a decrease in the rate of protein synthesis, its participation in fat, carbohydrate, pigment, water-electrolyte metabolism decreases, detoxification function and vitamin synthesis are inhibited. That is, the involutive effect on the structure and functional activity of the liver during the aging process, the presence of comorbidity and features of structural and functional changes in MAFLD in elderly people require a special approach in choosing tactics for managing this group of patients. The review article examines data from scientific studies on the prevalence and diagnosis of MAFLD, taking into account involutive changes in the liver in elderly people.

metabolically associated fatty liver disease, non-alcoholic fatty liver disease, aging, involutory changes, old age

1. World Health Organization. Obesity and Overweight. Geneva: World Health Organization; 2020. (Available at: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight Accessed: 2024 March 01).

2. Jeeyavudeen M., Khan S., Fouda S. Pappachan J. Management of metabolic-associated fatty liver disease: The diabetology perspective. World J Gastroenterol. 2023;29(1):126-143. doi: 10.3748/wjg.v29.i1.126.

3. Eslam M., Newsome P., Sarin S. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol.2020;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039.

4. Cusi K., Isaacs S., Barb D. et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.

5. Vlasov N. N., Kornienko E. A. Non-alcoholic fatty liver disease and metabolic syndrome in childhood. Experimental and Clinical Gastroenterology. 2020;183(11):51-61. (In Russ.) doi: 10.31146/1682-8658-ecg-183-11-51-61.@@ Власов Н. Н., Корниенко Е. А. Неалкогольная жировая болезнь печени и метаболический синдром в детском возрасте. Экспериментальная и клиническая гастроэнтерология.2020;183(11):51-61.doi: 10.31146/1682-8658-ecg-183-11-51-61.

6. Buturova L. I. Non-alcoholic fatty liver disease as a manifestation of metabolic syndrome: epidemiology, pathogenesis, clinical manifestations, principles of diagnosis, modern treatment options. Moscow, Forte print, 2012, 52p. (In Russ.) EDN: QMCEMX.@@ Буторова Л. И. Неалкогольная жировая болезнь печени как проявление метаболического синдрома: эпидемиология, патогенез, особенности клинического проявления, принципы диагностики, современные возможности лечения: Пособие для врачей. М.: Форте принт, 2012. 52с. EDN: QMCEMX.

7. Yi M., Peng W., Feng X. et al. Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses. Aliment Pharmacol Ther. 2022;56(7):1119-1130. doi: 10.1111/apt.17165.

8. Minhas A., Jain V., Maqsood M. et al. Non-Alcoholic Fatty Liver Disease, Heart Failure, and Long-Term Mortality: Insights From the National Health and Nutrition Examination Survey. Curr Probl Cardiol. 2022;47(12):101333. doi: 10.1016/j.cpcardiol.2022.101333.

9. Wong V., Wong G., Woo J. et al. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. Clin Gastroenterol Hepatol. 2021; 19(10):2161-2171.e5. doi: 10.1016/j.cgh.2020.10.046.

10. Lin S., Huang J., Wang M. et al.Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020; 40(9):2082-2089. doi: 10.1111/liv.14548.

11. Ayada I., van Kleef L., Alferink L. et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. Liver Int. 2022;42(2):277-287. doi: 10.1111/liv.15139.

12. Younossi Z., Koenig A., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease. Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431.

13. Koehler E., Schouten J., Hansen B. et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol. 2012;57(6):1305-11. doi: 10.1016/j.jhep.2012.07.028.

14. Hartleb M., Barański K., Zejda J. et al. Non-alcoholic fatty liver and advanced fibrosis in the elderly: Results from a community-based Polish survey. Liver Int. 2017;37(11):1706-1714. doi: 10.1111/liv.13471.

15. Chen T., Lai M., Lin W. et al. Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study. J Gastroenterol Hepatol. 2020;35(9):1636-1643. doi: 10.1111/jgh.15073.

16. Population Division, United Nations Department of Economic and Social Affairs, Population Estimates and Projections Section, World Population Prospects: The 2012 Revision (New York: United Nations Department of Economic and Social Affairs, 2014). (Available at: http://esa.un.org/unpd/wpp/index.htm. Accessed: 05.03.2024.)

17. Abegunde D., Mathers C., Adam T. et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007;370(9603):1929-38. doi: 10.1016/S0140-6736(07)61696-1.

18. Parambi D., Unnikrishnan M., Marathakam A., Mathew B. Demographic and Epidemiological Aspects of Aging. In: Nabavi, S.M., D’Onofrio, G., Nabavi, S.F. (eds) Nutrients and Nutraceuticals for Active & Healthy Ageing. 2020;1:1-14. doi: 10.1007/978-981-15-3552-9_1.

19. Omran A. The epidemiologic transition: a theory of the epidemiology of population change. 1971. Milbank Q. 2005;83(4):731-57. doi: 10.1111/j.1468-0009.2005.00398.x.

20. Bloom D., Canning D., Lubet A. Global Population Aging: Facts, Challenges, Solutions & Perspectives. Journal of the American Academy of Arts & Sciences. 2015;144(2):80-92. doi: 10.1162/DAED_a_00332.

21. Schmucker D. Age-related changes in liver structure and function: Implications for disease? Exp Gerontol. 2005;40(8-9):650-9. doi: 10.1016/j.exger.2005.06.009.

22. Lazebnik L. B. Age changes in the digestive system. Clin. gerontol. 2006;12(1): 3-8. (In Russ.) EDN: JUUHZX.@@ Лазебник Л. Б. Возрастные изменения пищеварительной системы. Клин. геронтол. 2006;12(1): 3-8. EDN: JUUHZX.

23. Lazebnik L. B., Turkina S. V. NAFLD Associated Comorbidity. Experimental and Clinical Gastroenterology. 2021;(10):5-13. (In Russ.) doi:10.31146/1682-8658-ecg-194-10-5-13.@@ Лазебник Л. Б., Туркина С. В. НАЖБП - ассоциированная коморбидность. Экспериментальная и клиническая гастроэнтерология. 2021;10(194):5-13. doi: 10.31146/1682-8658-ecg-194-10-5-13.

24. Lazebnik L.B., Ilchenko L. Y. Age-related changes in the liver (clinical and morphologic aspects). Clinical Gerontology. 2007;13(1): 3-8. (In Russ.)@@ Лазебник Л. Б., Ильченко Л. Ю. Возрастные изменения печени (клинические и морфологические аспекты). Клиническая геронтология. 2007;13(1): 3-8.

25. Ghavimi S., Azimi H., Patel N., Shulik O. Geriatric Hepatology: The Hepatic Diseases of the Elderly and Liver Transplant. J Dig Dis Hepatol. 2019.3.167p. doi: 10.29011/2574-3511.000067.

26. Sheedfar F., Di Biase S., Koonen D., Vinciguerra M. Liver diseases and aging: friends or foes? Aging Cell. 2013;12(6):950-954. doi: 10.1111/acel.12128.

27. Hilmer S., Cogger V., Le Couteur D. Basal activity of Kupffer cells increases with old age. J Gerontol A Biol Sci Med Sci. 2007;62(9):973-8. doi: 10.1093/gerona/62.9.973.

28. Warren A., Cogger V. C., Fraser R. et al. The effects of old age on hepatic stellate cells. Curr Gerontol Geriatr Res. 2011:439835. doi: 10.1155/2011/439835.

29. Verma S., Tachtatzis P., Penrhyn-Lowe S. et al. Sustained telomere length in hepatocytes and cholangiocytes with increasing age in normal liver. Hepatology. 2012;56(4):1510-1520. doi: 10.1002/hep.25787.

30. Kalinin A. L. The morphological and pathophysiological features of the liver in elderly patients. Health and Ecology Issues. 2016;(1):13-17. (In Russ.) doi: 10.51523/2708-6011.2016-13-1-3.@@ Калинин А. Л. Морфологические и патофизиологические особенности печени у пожилых пациентов. Проблемы здоровья и экологии. 2016;(1):13-17. doi: 10.51523/2708-6011.2016-13-1-3.

31. Gan L., Chitturi S., Farrell G. Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly. Curr Gerontol Geriatr Res. 2011;2011:831536. doi: 10.1155/2011/831536.

32. Klotz U. Pharmacokinetics and drug metabolism in the elderly.Drug Metab Rev. 2009;41(2):67-76. doi: 10.1080/03602530902722679.

33. Wauthier V., Verbeeck R. K., Calderon P. B. The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. Curr Med Chem. 2007;14(7):745-57. doi: 10.2174/092986707780090981.

34. Slawik M., Vidal-Puig A. Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res Rev. 2006;5(2):144-164. doi: 10.1016/j.arr.2006.03.004.

35. McPherson S., Hardy T., Dufour J. et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740-751. doi: 10.1038/ajg.2016.453.

36. Noureddin M., Yates K., Vaughn I. et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58(5):1644-1654. doi: 10.1002/hep.26465.

37. Frith J., Day C., Henderson E. et al. Non-alcoholic fatty liver disease in older people. Gerontology. 2009;55(6):607-613. doi: 10.1159/000235677.

38. Tallarico V., Recinella G., Magalotti D. et al. Prognostic value of non-alcoholic fatty liver disease in the elderly patients. Aging Clin Exp Res. 2020;32(12):2657-2665. doi: 10.1007/s40520-020-01487-2.

39. Skelly M., James P., Ryder S. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 2001;35(2):195-9. doi: 10.1016/s0168-8278(01)00094-0.

40. Neuschwander-Tetri B., Caldwell S. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202-19. doi: 10.1053/jhep.2003.50193.

41. Sorrentino P., Tarantino G., Conca P. et al. Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol. 2004;41(5):751-7. doi: 10.1016/j.jhep.2004. 07.010.

42. Fracanzani A., Valenti L., Bugianesi E. et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol. 2011;54(6):1244-9. doi:10.1016/j.jhep.2010.09.037.

43. Pitisuttithum P., Chan W., Piyachaturawat P. et al. Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. BMC Gastroenterol. 2020;20(1):88. doi: 10.1186/s12876-020-01240-z.

44. Zhou M., Zhu N., Yu C. et al. Analysis on adulthood weight change in adults in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2019;40(5):510-514. Chinese. doi: 10.3760/cma.j.issn.0254-6450.2019.05.004.

45. Yamada G., Hagiwara Y., Kimura T. et al. Impact of Body Weight Gain on the Incidence of Nonalcoholic Fatty Liver Disease in Nonobese Japanese Individuals. Am J Gastroenterol. 2021;116(4):733-740. doi: 10.14309/ajg.0000000000001030.

46. Zhao Y., Zhao G., Chen Z. et al. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertension. 2020;75(2):275-284. doi: 10.1161/HYPERTENSIONAHA.119.13419.

47. Ciardullo S., Grassi G., Mancia G., Perseghin G. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022;34(4):365-371. doi: 10.1097/MEG.0000000000002299.

48. Wang B., Li M., Zhao Z. et al. Glycemic Measures and Development and Resolution of Nonalcoholic Fatty Liver Disease in Nondiabetic Individuals. J Clin Endocrinol Metab. 2020;105(5): dgaa112. doi: 10.1210/clinem/dgaa112.

49. Wei F., Li J., Chen C. et al. Higher Serum Uric Acid Level Predicts Non-alcoholic Fatty Liver Disease: A 4-Year Prospective Cohort Study. Front Endocrinol (Lausanne). 2020;11:179p. doi: 10.3389/fendo.2020.00179.

50. Ong J., Pitts A., Younossi Z. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49(4):608-12. doi: 10.1016/j.jhep.2008.06.018.

51. Stepanova M., Rafiq N., Makhlouf H. et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58(10):3017-23. doi: 10.1007/s10620-013-2743-5.

52. Lin H., Yip T., Zhang X. et al.Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease. Hepatology. 2023;77(2):573-584. doi: 10.1002/hep.32633.

53. Zhang X., Wong G., Yip T. et al. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. Hepatology. 2022;76:1409-1422. doi: 10.1002/hep.32476.

54. De Vincentis A., Costanzo L., Vespasiani-Gentilucci U. et al. Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people. Dig Liver Dis. 2019;51(9):1330-1336. doi: 10.1016/j.dld.2019.01.017.

55. Valbusa F., Bonapace S., Agnoletti D. et al. Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS One. 2017; 12(3): e0173398. doi: 10.1371/journal.pone.0173398.